Skip to main content

Table 1 Basic clinicopathological data for hepatitis B patients included

From: Development of a non-invasive fibrosis test for chronic hepatitis B patients and comparison with other unpatented scores

Characteristics Training cohort Verification
  (n = 213) cohort (n = 211)
Age at biopsy in years, mean ± SD 44.4 ± 11.8 45.6 ± 11.4
Male, n (%) 179 (84) 175 (83)
Biopsy   
Necroinflammation score, mean ± SD
  Periportal inflammation 1.0 ± 0.8 0.9 ± 0.8
  Confluence necrosis 0.3 ± 1.0 0.2 ± 0.8
  Focal inflammation 1.9 ± 0.7 2.0 ± 0.7
  Portal inflammation 2.2 ± 1.0 2.2 ± 0.9
ISHAK fibrosis score, n (%)   
  0 1 (1) 1 (1)
  1 28 (13) 28 (13)
  2 32 (15) 32 (15)
  3 70 (33) 71 (34)
  4 21 (10) 21 (10)
  5 46 (22) 45 (21)
  6 15 (7) 13 (6)
HBeAg-positive, n (%) 109 (51) 91 (43)
Biochemistry, mean ± SD   
AST (IU/mL) 91.3 ± 83.6 94.9 ± 100.1
ALT (IU/mL) 170.1 ± 173.8 166.2 ± 177.9
AST/ALT 0.6 ± 0.3 0.6 ± 0.3
AFP (ng/mL) 10.5 ± 22.2 20.4 ± 82.0
Bilirubin (mg/dL) 1.0 ± 0.7 1.0 ± 0.4
GGT (IU/L) 69.0 ± 77.0 60.1 ± 57.3
Albumin (g/dL) 4.6 ± 0.3 4.5 ± 0.4
Platelet (×103/mm3) 188.2 ± 54.2 189.2 ± 49.4
Prothrombin time prolongation (sec) 1.0 ± 0.6 1.0 ± 0.8
White blood cell (×103/mm3) 5.7 ± 1.7 5.5 ± 1.6
Hemoglobin (g/dL) 15.1 ± 1.4 15.2 ± 1.3
Alpha-1 globulin (g/dL) 0.2 ± 0.1 0.2 ± 0.0
Alpha-2 globulin (g/dL) 0.8 ± 0.2 0.8 ± 0.1
Beta globulin (g/dL) 0.8 ± 0.1 0.7 ± 0.1
Gamma globulin (g/dL) 1.5 ± 0.4 1.4 ± 0.4
Albumin/Globulin 1.5 ± 0.3 1.5 ± 0.3